Antimurine antibody to OKT3 in cardiac transplantation: implications for prophylaxis and retreatment of rejection.
O'Connell
J B
JB
Utah Transplantation Affiliated Hospitals (U.T.A.H.) Cardiac Transplant Program, Salt Lake City.
Bristow
M R
MR
Hammond
E H
EH
Menlove
R L
RL
Ensley
R D
RD
Ratkovec
R M
RM
Renlund
D G
DG
D000818:Animals; D000888:Antibodies, Anti-Idiotypic / Q000276:immunology*; D000911:Antibodies, Monoclonal / Q000276:immunology* / Q000627:therapeutic use; D009202:Cardiomyopathies / Q000150:complications; D003327:Coronary Disease / Q000150:complications; D006084:Graft Rejection; D016027:Heart Transplantation / Q000276:immunology*; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods; D051379:Mice; D016853:Muromonab-CD3; D016019:Survival Analysis
D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D016853:Muromonab-CD3